Current Status and Trends in the Development of China’s API Industry
Release date:
2019-02-18
According to statistics from the Price Monitoring and Competition Bureau of the National Development and Reform Commission, China is capable of producing more than 1,500 types of active pharmaceutical ingredients, with a total output reaching one million tons and exports accounting for over 60 percent. As a result, China has become the world’s second-largest producer of APIs—behind only the United States—and its largest exporter.
According to statistics from the Price Monitoring and Competition Bureau of the National Development and Reform Commission, China is capable of producing more than 1,500 types of active pharmaceutical ingredients, with a total output reaching one million tons and export volumes accounting for over 60 percent. As a result, China has become the world’s second-largest producer of APIs—after the United States—and its largest exporter.
Current Status of the API Industry in China
In recent years, as the number of patented drugs approaching patent expiration has continued to grow, the variety and volume of generic drugs have also risen rapidly, creating substantial market opportunities for the active pharmaceutical ingredient (API) sector and driving a steady increase in API production.
Meanwhile, driven by rising production and environmental compliance costs in Europe and the United States, coupled with improvements in Chinese API manufacturers’ process technologies, production quality, and regulatory‑market registration and certification capabilities, a significant number of API producers have accelerated their relocation to China, leading to a continuous expansion of the country’s API production capacity. According to statistics, in 2017, China’s cumulative output of chemical APIs reached 3.478 million tons, up 1.6% year on year.
The chemical API industry has seen steady growth in main business revenue, rising from RMB 328.972 billion in 2012 to RMB 573.475 billion in 2017. Total profits amounted to RMB 48.644 billion, yet the profit margin remained low, standing at 8.48% in 2017.
At present, China’s API industry is predominantly focused on bulk APIs, leaving substantial room for growth in specialty APIs and APIs for patented drugs. In the chemical pharmaceutical sector, APIs are conventionally categorized into three major groups: bulk APIs, specialty APIs, and APIs for patented medicines.
(1) Bulk active pharmaceutical ingredients: overcapacity and low prices.
Bulk active pharmaceutical ingredients (APIs) primarily include vitamins, antibiotics, and hormones. Among these, vitamin C, erythromycin thiocyanate, penicillin, azithromycin, and semi‑synthetic cephalosporin APIs are the products most heavily affected by new production capacity and overcapacity in the industry.
At present, China has more than 8,000 API manufacturers, but the majority still focus on producing bulk APIs with relatively low technological content. As supply-side structural reform advances, the production of bulk APIs in China will become increasingly concentrated, and manufacturing processes will continue to improve.
It is foreseeable that, in the future, China’s production capacity and output of bulk active pharmaceutical ingredients will decline, bringing supply and demand into greater balance. Prices and profit margins will gradually return to more reasonable levels, and the era of historically low prices will be a thing of the past. Moreover, certain API varieties may even lose their price competitiveness and shift production overseas.
(2) Specialty APIs: Production capacity continues to expand, with a focus on generic APIs for originator drugs whose patents have expired—particularly in categories such as cardiovascular, antiviral, and anti‑cancer agents. These products are characterized by high technological content and robust profitability, making this segment one of the most dynamic in China over the past decade. It has played a pivotal role in the rise of companies like Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical.
In 2016, China’s exports of specialty APIs reached US$3.53 billion, accounting for 13.8% of total API exports. With approximately US$194 billion worth of originator drugs set to lose patent protection over the next five years, an increasing number of domestic companies are focusing on the corresponding specialty APIs and have already begun R&D and production preparations. As a result, China’s production and export volumes of specialty APIs are expected to continue expanding and growing in the years ahead.
(3) Patented API: China’s CMO sector ranks among the world’s top, with future growth expected at 20%–30%. Amid an increasingly integrated global landscape of pharmaceutical capacity‑sharing, some multinational pharmaceutical companies are abandoning their traditional vertically integrated business models, shifting their focus to market‑driven operations. By outsourcing R&D, clinical trials, and manufacturing, they aim to reduce costs, giving rise to the demand for patented APIs.
China’s pharmaceutical CMO market has maintained a growth rate of over 10% in recent years. From a market‑structure perspective, clinical‑stage manufacturing is expanding at an average annual rate of 9.5%, while commercial‑stage production is expected to grow at an average rate of 18.7%.
It is estimated that China’s CMO market has already reached approximately US$5 billion. With the implementation and further advancement of the Marketing Authorization Holder (MAH) system in China, the domestic pharmaceutical CMO industry is poised for rapid growth, with projections indicating an annual expansion rate of 20% to 30%. Among these, patented active pharmaceutical ingredients (APIs) account for a significant share.
The API industry exhibits a high degree of concentration, yet its enterprises are unevenly distributed across regions and product lines.
According to statistics from the Huoshi Creative database, China currently has more than 2,400 enterprises licensed to produce pharmaceutical APIs. Geographically, Jiangsu and Zhejiang account for the largest concentration of API manufacturers, with over 300 companies each, followed by Shandong, Sichuan, Hubei, and other regions.
Meanwhile, Linhai in Zhejiang Province has established a national-level chemical API base, making it one of the earliest and largest agglomeration hubs for the chemical API and pharmaceutical intermediate industries in China. In addition, as environmental regulatory pressures mount, nearly a hundred Beijing‑based pharmaceutical companies have concentrated around the Bohai Bay, giving rise to the nascent northern China API manufacturing base.
Today, China is not only one of the world’s largest producers and exporters of active pharmaceutical ingredients (APIs), but it also exhibits a notably high degree of industrial concentration. According to the “API Product and Market Analysis Report” published by Yaosu.com in 2017, manufacturers of APIs and related intermediates are predominantly concentrated in regions traditionally characterized by a robust chemical industry, with Zhejiang, Shandong, and Hebei serving as prime examples.
In the 2017 Top 50 list of API‑exporting companies, geographic clustering among leading firms remained pronounced: Zhejiang’s Huahai and Prole, Hebei’s Shiyao Group, and Shandong’s Xinhua Pharmaceutical and Xinfa Pharmaceutical all secured strong rankings. Globally, Chinese API manufacturers also delivered solid performance. According to the U.S.-based Transparent Pharma website, in 2016, Chinese pharmaceutical companies accounted for six of the top ten players in the global API market, with Zhejiang-based firms securing four spots among the world’s top ten API producers.
From the perspective of product structure, these companies’ product portfolios are primarily concentrated in vitamins, antipyretic‑analgesics, antibiotics, and corticosteroids. Taking penicillin industrial salts and vitamin C as examples, these two represent China’s two major strategic APIs and also epitomize severe overcapacity.
Related News
Leave a Message Online
Consultation Service Hotline
Address: No. 509, East Lin Road, Bio-Industrial Park, High-tech Zone, Yichang City, Hubei Province, China
International Marketing Department
Contact: Vivian Guo
Email: Vivian.guo@tianrenpharm.com
Phone: 86-15997560212
WhatsApp: +86-15997560212
Website Development:China Enterprise Dynamics Yichang right of privacy
This website supports both IPv4 and IPv6 bidirectional access.